CAS: 62733-99-7; Methyl 3-Hydroxypicolinate

相似化合物

874-24-8 1849-55-4 14173-30-9

上下游产品

CAS号67-56-1 甲醇 | CAS号874-24-8 3-羟基-2-吡啶甲酸 | CAS号36851-80-6 亚硝基甲基脲 | CAS号186581-53-3 重氮甲烷 | CAS号943777-92-2 2-Pyridinecarbo... | CAS号24059-83-4 3-甲氧基吡啶-2-甲酸甲酯 | CAS号59718-84-2 3-甲基吡啶-2-甲酸甲酯 | CAS号103863-15-6 3-苯基-2-吡啶甲酸 | CAS号321601-48-3 6-溴-3-羟基吡啶-2-甲酸甲酯 | CAS号321596-55-8 4,6-二溴-3-羟基吡啶甲酸甲酯 | CAS号14623-54-2 3-巯基甲酸吡啶盐酸盐 | CAS号366457-52-5 2-Pyridinecarbo... | CAS号593287-44-6 2-Pyridinecarbo... | CAS号62734-00-3 methyl 3-methox... | CAS号4116-88-5 3-ethylpyridine...

3-羟基-2-吡啶甲酸置于三氟化硼,碳酸氢钠体系中,化学反应生成 3-羟基-2-吡啶甲酸甲酯
参考文献:Alkoxy Pyridine Compounds
标题:Alkoxy Pyridine Compounds
摘要:这些化合物是组织胺h.Sub.2-拮抗剂的烷氧基吡啶化合物.本发明的两种特定化合物是n-氰基-N'-甲基-N"-[2-((3-甲氧基-2-吡啶基)甲硫基)乙基]胍和1-甲氨基-1-[2-(3-甲氧基-2-吡啶基)甲硫基)乙基氨基]-2-硝基乙烯.

专利信息

专利号:US-9364482-B2
优先权日:2013-06-24
标 题 :Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
发明人：DAI XING; LIU HONG; PALANI ANANDAN; HE SHUWEN; NARGUND RAVI; XIAO DONG; ZORN NICOLAS; DANG QUN; MCCOMAS CASEY C; PENG XUANJIA; LI PENG; SOLL RICHARD
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. (I)

专利号:US-9242998-B2
优先权日:2013-02-07
标题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
发明人：HE SHUWEN; DAI XING; PALANI ANANDAN; NARGUND RAVI; LAI ZHONG; ZORN NICOLAS; XIAO DONG; DANG QUN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD
权利人:HE SHUWEN; DAI XING; PALANI ANANDAN; NARGUND RAVI; LAI ZHONG; ZORN NICOLAS; XIAO DONG; DANG QUN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.